<DOC>
	<DOC>NCT01121770</DOC>
	<brief_summary>The purpose of this study is to determine a preventative dose of study drug, Arixtra速 for patients with kidney disease. We will measure the blood levels of Arixtra速 in patients with kidney disease and develop guidelines for dosing.</brief_summary>
	<brief_title>"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Inpatients who are 18 years or older estimated creatinine clearances between 2050 ml/min current hospitalization for a cancerrelated abdominal, breast surgery or elective orthopedic surgery able to give informed consent need for prophylactic anticoagulant therapy for increased risk of a thrombotic episode Use of the following clopidogrel, aspirin, or NSAID usage,(usage is prohibited while patients are participating in the study) body weight &lt; 50 kg anticoagulation therapy for thrombosis or other indication pregnant or breastfeeding hypersensitivity to Arixtra速 thrombocytopenia associated with a positive in vitro test for antiplatelet antibody in the presence of Arixtra速 bacterial endocarditis brain malignancy increased risk of bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>